Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast
The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint inhibitor combination therapies. We expect that label expansions of Opdivo (Bristol Myers Squibb) and Keytruda (Merck & Co.), as well as approvals of other programmed death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) inhibitors, will continue to reshape the human epidermal growth factor receptor-2 (HER2)-negative gastroesophageal cancer market in the coming years. Immune checkpoint inhibitors in combination with HER2-targeted agents and chemotherapy, and the anti-HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo / AstraZeneca) are poised to expand treatment options for HER2-positive patients. Other treatments are targeting niche biomarkers (e.g., claudin18.2, FGFR2b) and are set to provide novel treatment options for select gastroesophageal cancer patients. Given the intense late-phase pipeline activity, we anticipate the approval of several new therapies for gastroesophageal cancer during the forecast period.
Questions answered
- How is gastroesophageal cancer segmented by subpopulation, and how will the recent drug approvals and label expansions to the various subpopulations impact the market?
- What are the key current therapies in gastroesophageal cancer, and how are they positioned in the treatment algorithm?
- Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer market?
- What are the drivers and constraints in the gastroesophageal cancer market, and how will the market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Gastroesophageal Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- January 2023
- Q4 2022
- December 2022
- Q3 2022
- July 2022
- Q2 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2021
- December 2021
- Market outlook
- Key findings
- Major-market share of drug classes in gastroesophageal cancer: 2021
- Major-market share of drug classes in gastroesophageal cancer: 2031
- Major-market sales of key therapies for gastroesophageal cancer: 2021-2031
- Drug-treatable population share and major-market sales share in gastroesophageal cancer: 2021
- Drug-treatable population share and major-market sales share in gastroesophageal cancer: 2031
- Population positioning of therapies in gastric and GEJ cancer: United States and Europe
- Population positioning of therapies in gastric and GEJ cancer: Japan
- Population positioning of therapies in esophageal cancer: United States and Europe
- Population positioning of therapies in esophageal cancer: Japan
- Gastroesophageal cancer SWOT analysis
- Market drivers and constraints
- What factors are driving the market for gastroesophageal cancer?
- What factors are constraining the market for gastroesophageal cancer?
- Segment-specific trends
- Patient-share dynamics of key regimens in resectable gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in resectable esophageal cancer in the United States: 2021-2031
- Patient-share dynamics of key regimens in unresectable locally advanced HER2-negative gastric and GEJ adenocarcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in unresectable locally advanced HER2-positive gastric and GEJ adenocarcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in unresectable locally advanced esophageal cancer in the United States: 2021-2031
- Patient-share dynamics of key regimens in first-line metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in first-line metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
- First-line metastatic esophageal adenocarcinoma and squamous cell carcinoma
- Patient-share dynamics of key regimens in first-line metastatic esophageal adenocarcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in first-line metastatic esophageal squamous cell carcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in second-line metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in second-line metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in second- and third-line metastatic esophageal adenocarcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in second- and third-line metastatic esophageal squamous cell carcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in third- and fourth-line metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
- Patient-share dynamics of key regimens in third- and fourth-line metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma in the United States: 2020-2030
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Disease pathophysiology
- Anatomy of the stomach and the gastroesophageal junction
- Anatomy of the esophagus
- Subtype classification and development of gastric and gastroesophageal junction adenocarcinoma
- Key stages in the development of intestinal and diffuse types of gastric andu00a0gastroesophageal junctionu00a0adenocarcinoma
- Subtype classification and development of esophageal cancer
- Key stages in the development of esophageal cancer
- Staging and classification
- AJCC / UICC TNM classification system for gastroesophageal cancer
- AJCC / UICC clinical staging classification system for gastroesophageal cancer
- AJCC / UICC pathological staging classification system for gastroesophageal cancer
- AJCC / UICC postneoadjuvant therapy staging classification system for gastroesophageal cancer
- Key pathways and drug targets
- Drug targets and potential therapies for gastroesophageal cancer
- Drug targets for gastroesophageal cancer
- Biology of immune checkpoint inhibitors and modulators
- Disease overview
- Epidemiology
- Introduction
- Key findings
- Epidemiology populations
- Disease definition
- Methods and sources used
- Number of diagnosed incident cases of gastroesophageal cancer: 2021-2031
- Definition
- Methods and sources used
- Diagnosed incident cases of gastric and GEJ adenocarcinoma by stage distribution: 2021-2031
- Diagnosed incident cases of esophageal adenocarcinoma by stage distribution: 2021-2031
- Diagnosed incident cases of esophageal squamous cell carcinoma by stage distribution: 2021-2031
- Definition
- Methods and sources used
- Recurrent incident cases of gastroesophageal cancer: 2021-2031
- Definition
- Methods and sources used
- Molecular subtype: 2021-2031
- Gastric and gastroesophageal junction adenocarcinoma patient flow
- Esophageal adenocarcinoma patient flow
- Esophageal squamous cell carcinoma patient flow
- Drug-treatable cases of gastroesophageal cancer: 2021-2031
- Drug-treated populations
- Drug-treated cases of gastroesophageal cancer: 2021-2031
- Introduction
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for gastroesophageal cancer
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for gastroesophageal cancer
- Current treatments used for gastroesophageal cancer
- Market events impacting the use of key current therapies for gastroesophageal cancer
- Key results from select clinical trials investigating Cyramza for the treatment of gastroesophageal cancer
- Ongoing clinical development of Cyramza
- Key ongoing clinical trials of Cyramza in the treatment of gastroesophageal cancer
- Expert insight: Cyramza
- Key results from select clinical trials investigating trastuzumab for the treatment of gastroesophageal cancer
- Ongoing clinical development of trastuzumab
- Expert insight: trastuzumab
- Key results from select clinical trials investigating Enhertu for the treatment of gastroesophageal cancer
- Ongoing clinical development of Enhertu
- Key ongoing clinical trials of Enhertu in the treatment of gastroesophageal cancer
- Expert insight: Enhertu
- Key results from select clinical trials investigating Keytruda for the treatment of gastroesophageal cancer
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of gastroesophageal cancer
- Expert insight: Keytruda
- Key results from select clinical trials investigating Opdivo for the treatment of gastroesophageal cancer
- Ongoing clinical development of Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of gastroesophageal cancer
- Expert insight: Opdivo
- Lonsurf
- Key results from select clinical trials investigating Lonsurf for the treatment of gastroesophageal Cancer
- Ongoing clinical development of Lonsurf
- Expert insights: Lonsurf
- Medical practice
- Localized and resectable locally advanced gastroesophageal cancer
- Unresectable locally advanced gastroesophageal cancer
- First-line metastatic gastroesophageal cancer
- Second-line gastroesophageal cancer
- Patient characteristics influencing drug selection in gastroesophageal cancer
- Region-specific treatment practices
- Treatment decision tree for drug-treatable gastric and gastroesophageal junction adenocarcinoma: United States
- Treatment decision tree for drug-treatable esophageal cancer: United States
- Treatment decision tree for drug-treatable gastric and gastroesophageal junction adenocarcinoma: Europe
- Treatment decision tree for drug-treatable esophageal cancer: Europe
- Treatment Decision Tree for drug-treatable Gastric and Gastroesophageal Junction Adenocarcinoma: Japan
- Treatment Decision Tree for drug-treatable Esophageal Cancer: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in gastroesophageal cancer
- Top unmet needs in gastroesophageal cancer: current and future attainment
- Expert insights: unmet need in gastroesophageal cancer
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for gastroesophageal cancer
- Estimated market authorization dates of key emerging therapies for the treatment of gastroesophageal cancer
- Key results from select clinical trials investigating tislelizumab for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of tislelizumab in the treatment of gastroesophageal cancer
- Analysis of clinical development program for tislelizumab
- Expert insight: tislelizumab
- Expectations for market authorization and sales opportunity of tislelizumab in gastroesophageal cancer
- Key results from select clinical trials investigating Imfinzi for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of Imfinzi in the treatment of gastroesophageal cancer
- Analysis of clinical development program for Imfinzi
- Expert insight: Imfinzi
- Expectations for market authorization and sales opportunity of Imfinzi in gastroesophageal cancer
- Key results from select clinical trials investigating Tecentriq / Tecentriq plus tiragolumab for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of Tecentriq / Tecentriq plus tiragolumab in the treatment of gastroesophageal cancer
- Analysis of clinical development program for Tecentriq / Tecentriq plus tiragolumab
- Expert insights: Tecentriq / Tecentriq plus tiragolumab
- Expectations for market authorization and sales opportunity of Tecentriq / Tecentriq plus tiragolumab in gastroesophageal cancer
- Key results from select clinical trials investigating Tyvyt for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of Tyvyt in the treatment of gastroesophageal cancer
- Analysis of clinical development program for Tyvyt
- Expert insights: Tyvyt
- Expectations for market authorization and sales opportunity of Tyvyt in gastroesophageal cancer
- Key results from select clinical trials investigating evorpacept for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of evorpacept in the treatment of gastroesophageal cancer
- Analysis of clinical development program for evorpacept
- Expectations for market authorization and sales opportunity of evorpacept in gastroesophageal cancer
- Key results from select clinical trials investigating zanidatamab for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of zanidatamab in the treatment of gastroesophageal cancer
- Analysis of clinical development program for zanidatamab
- Expert insight: zanidatamab
- Expectations for market authorization and sales opportunity of zanidatamab in gastroesophageal cancer
- Key results from select clinical trials investigating Margenza for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of Margenza in the treatment of gastroesophageal cancer
- Analysis of clinical development program for Margenza
- Expectations for market authorization and sales opportunity of Margenza in gastroesophageal cancer
- Tukysa
- Key ongoing clinical trials of Tukysa in the treatment of gastroesophageal cancer
- Analysis of clinical development program for Tukysa
- Expert insight: Tukysa
- Expectations for market authorization and sales opportunity of Tukysa in gastroesophageal cancer
- Key results from select clinical trials investigating rivoceranib for the treatment of gastroesophageal cancer
- Analysis of clinical development program for rivoceranib
- Expert insight: rivoceranib
- Expectations for market authorization and sales opportunity of rivoceranib in gastroesophageal cancer
- Key results from select clinical trials investigating Stivarga for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of Stivarga in the treatment of gastroesophageal cancer
- Analysis of clinical development program for Stivarga
- Expert insight: Stivarga
- Expectations for market authorization and sales opportunity of Stivarga in gastroesophageal cancer
- Key results from select clinical trials investigating Lenvima for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of Lenvima in the treatment of gastroesophageal cancer
- Analysis of the clinical development program for Lenvima
- Expert insight: Lenvima
- Expectations for market authorization and sales opportunity of Lenvima in gastroesophageal cancer
- Key results from select clinical trials investigating zolbetuximab for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of zolbetuximab in the treatment of gastroesophageal cancer
- Analysis of clinical development program for zolbetuximab
- Expert insight: zolbetuximab
- Bemarituzumab
- Key results from select clinical trials investigating bemarituzumabu00a0for the treatment of gastroesophageal cancer
- Key ongoing clinical trials of bemarituzumab in the treatment of gastroesophageal cancer
- Analysis of clinical development program for bemarituzumabu00a0
- Expert insight: bemarituzumab
- Expectations for market authorization and sales opportunity of bemarituzumab in gastroesophageal cancer
- Early-phase pipeline analysis
- Select compounds in early-phase development for gastroesophageal cancer
- Key findings
- Access and reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in gastroesophageal cancer: United States
- General reimbursement environment: United States
- Key market access considerations in gastroesophageal cancer: EU5
- General reimbursement environment: EU5
- Key market access considerations in gastroesophageal cancer: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Gastroesophageal cancer bibliography
- Key findings
Liseth Parra, Ph.D., is an analyst on the Oncology team at Clarivate. She has extensive background in oncology research and market analysis. She completed a postdoctoral fellowship in oncology at Brigham and Women’s Hospital in Boston, along with commercial work as an oncology research analyst for Kantar Health and as an independent consultant. She also worked as a research fellow at the Novartis Institutes for BioMedical Research in Basel, Switzerland, and at the Fritz Lipmann Institute in Jena, Germany. Dr. Parra completed her doctorate in neurosciences at the University of California in San Diego.
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.